Unknown

Dataset Information

0

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).

ABSTRACT:

SUBMITTER: Maruyama D 

PROVIDER: S-EPMC9459263 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).
| S-EPMC7891591 | biostudies-literature
Unknown Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
| S-EPMC11868237 | biostudies-literature
Unknown Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
| S-EPMC4123433 | biostudies-literature
Unknown Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.
| S-EPMC6900260 | biostudies-literature
Unknown A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
| S-EPMC4157818 | biostudies-literature
Unknown Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.
| S-EPMC12141397 | biostudies-literature
Unknown The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.
| S-EPMC8880219 | biostudies-literature
Unknown P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
| S-EPMC10171484 | biostudies-literature
Unknown Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
| S-EPMC2895039 | biostudies-literature
Unknown Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.
| S-EPMC4080410 | biostudies-literature